No-Spa Comfort (Drotaverine Hydrochloride)

Drotaverine works by selectively inhibiting phosphodiesterase‑4, which raises intracellular cyclic AMP levels in smooth‑muscle cells. The increased cAMP reduces calcium entry, leading to relaxation of smooth muscle. Its additional calcium‑antagonist activity further enhances the antispasmodic effect.

The dosage of No-Spa Comfort is determined by a qualified healthcare professional based on the individual’s condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for drotaverine during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so it should only be used if the potential benefit justifies the potential risk. Breastfeeding mothers should consult their physician before use.

To order No-Spa Comfort, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any required import documentation.

Compared with hyoscine butylbromide, another common antispasmodic, drotaverine has a distinct mechanism—selective PDE‑4 inhibition and calcium antagonism—rather than anticholinergic activity. This can result in fewer anticholinergic side effects such as dry mouth or blurred vision, while providing comparable relief of smooth‑muscle spasm.

Store No-Spa Comfort at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and keep them out of reach of children.

No-Spa Comfort is taken orally. The tablet should be swallowed whole with a glass of water, preferably after a meal unless otherwise directed by a healthcare professional.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, and rare cardiac arrhythmias. Patients experiencing signs of these conditions—such as rash, swelling, sudden drop in blood pressure, or irregular heartbeat—should seek immediate medical attention.

No-Spa Comfort should be avoided in individuals with known hypersensitivity to drotaverine or any excipients, in patients with severe hypotension, and in those for whom antispasmodic therapy is contraindicated. Caution is also advised for patients with significant cardiac, hepatic or renal impairment.